The core application of Flex Pharma’s ElectroNanoSpray™ (ENS) technology is to improve drug formulations, specifically to overcome limitations related to:
Overview of the INNOVATION
ElectroNanoSpray™ (ENS)
-
Innovation
Flex Pharma's proprietary commercial spray dryer, the Flex20X, utilizes ENS, a proprietary atomization technology.
-
Precision
ENS atomization uses electric field forces to generate fine droplets, resulting in amorphous drug particles of unparalleled size and uniformity.
-
Reliability
The process is highly repeatable, reproducible, and reliable, with the Flex20X having no moving parts or thermal drying inputs.
-
Efficiency
ENS is distinct from conventional spray drying methods and offers a wide operating space, ensuring robust performance with very high process yield (>95%).
Benefits
Low product stress
Operates at ambient pressure and temperature.
Highly uniform & homogeneous
Leverages fundamental laws of physics and electric-field principles.
Tunable
Offers design degrees of freedom across molecules, solvent systems, and particle size.
Highly Repeatable
Consistent outcomes governed by scientific principles.
Scalable
No change in primary particle characteristics or performance between bench-top and commercial scales.
High Yield
Leverages the basic principle that oppositely charged materials attract.
Applications
To explore partnership opportunities or learn more about our innovative pipeline, please get in touch.
Get in Touch-
- Poor drug solubility
- Bioavailability & variability
- Drug-drug interactions
- Food effects
- Dosage form limitations
-
Improving Drug Solubility and Bioavailability
Many drugs have poor aqueous solubility, leading to dissolution rate-limited absorption, low bioavailability, and large doses.
- ENS technology is designed to overcome poor drug solubility, which in turn improves bioavailability, allowing for smaller doses to achieve therapeutic drug levels.
-
Eliminating food effects
Poor drug solubility often results in large, positive food effects, often requiring patients to take medication in a fasted state, which can be burdensome, result in poor compliance, and in some cases result in serious toxicity risks.- Flex Pharma’s technology can eliminate food effects, removing the need for strict fasting windows and preventing the risk of toxic exposures.
-
Overcoming pH-Dependent Solubility
Many drugs are weak bases having pH-dependent solubility, meaning their solubility decreases with increasing pH. This can lead to reduced drug exposure and sub-therapeutic effects, especially when patients use acid-reducing agents or have elevated gastric pH (ie, achlorhydria).
- Flex Pharma's formulations, like next-generation Phyrago™, are designed to be impervious to pH, ensuring consistent drug exposure regardless of gastric pH, thereby enabling coadministration with acid-reducing agents.
-
Enabling Dosage Form Flexibility
Many drug products cannot be crushed, split, chewed, or sprinkled, which limits dosing options.- Flex Pharma’s ENS particles have been successfully formulated into crushable tablet and orally disintegrating tablet (ODT) formulations, providing attractive dosing options for pediatric patients and those with dysphagia.
Intellectual Property
All our development efforts are undertaken with an eye towards meaningful and appropriate protections for our intellectual property. Our key proprietary developments include:
-
Proprietary ElectroNanoSpray™ (ENS) Technology
Our core technology, ElectroNanoSpray™ (ENS), is a proprietary platform that enables precise and efficient drug formulation. This technology leverages electric fields to generate fine, uniform droplets for precise particle formation. The proprietary platform is a key component of our formulation capabilities.
-
Patented Formulations
Our drug formulation capabilities allow us to secure patent protection on specific proprietary formulations related to discrete therapeutic agents.
-
Patented Therapeutic Benefits
Our proprietary drug formulations are often associated with solving known problems with existing therapies, such as food effects and drug-drug interactions, allowing us to secure patent protections on specific therapeutic benefits.